secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001193125-26-151300
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia adopts bylaw amendments adding shareholder cure provision and exclusive federal forum clause
--------------------------------------------------------------------------------

- Added provision allowing shareholders to cure facially apparent deficiencies in timely nomination or proposal notices.
- Designated U.S. federal district courts as exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934, unless company consents otherwise.
- Amendments effective April 7, 2026, adopted by Board on recommendation of nominating and corporate governance committee.
- Fourth Amended and Restated Bylaws filed as Exhibit 3.1 to this Form 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526151300/0001193125-26-151300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526151300/d65395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-151300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer